These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10213617)

  • 1. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
    Loo TW; Clarke DM
    Biochemistry; 1999 Apr; 38(16):5124-9. PubMed ID: 10213617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
    Loo TW; Bartlett MC; Clarke DM
    Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
    Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
    Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains.
    Kwan T; Gros P
    Biochemistry; 1998 Mar; 37(10):3337-50. PubMed ID: 9521654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux.
    Tainton KM; Smyth MJ; Jackson JT; Tanner JE; Cerruti L; Jane SM; Darcy PK; Johnstone RW
    Cell Death Differ; 2004 Sep; 11(9):1028-37. PubMed ID: 15131592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism involved in generating the carboxyl-terminal half topology of P-glycoprotein.
    Han ES; Zhang JT
    Biochemistry; 1998 Aug; 37(34):11996-2004. PubMed ID: 9718325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier.
    He L; Liu GQ
    Acta Pharmacol Sin; 2002 May; 23(5):423-9. PubMed ID: 11978192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME; Podila L; Ely D; Almeida I
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2004 Sep; 43(38):12081-9. PubMed ID: 15379547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
    Garrigues A; Nugier J; Orlowski S; Ezan E
    Anal Biochem; 2002 Jun; 305(1):106-14. PubMed ID: 12018951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-stimulated ATPase activity of a deletion mutant of the human multidrug-resistance protein (MDR1).
    Welker E; Szabó K; Holló Z; Müller M; Sarkadi B; Váradi A
    Biochem Biophys Res Commun; 1995 Nov; 216(2):602-9. PubMed ID: 7488154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
    Acharya P; Tran TT; Polli JW; Ayrton A; Ellens H; Bentz J
    Biochemistry; 2006 Dec; 45(51):15505-19. PubMed ID: 17176072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
    Martin C; Berridge G; Higgins CF; Callaghan R
    Br J Pharmacol; 1997 Oct; 122(4):765-71. PubMed ID: 9375975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of chemical chaperones in the yeast Saccharomyces cerevisiae to enhance heterologous membrane protein expression: high-yield expression and purification of human P-glycoprotein.
    Figler RA; Omote H; Nakamoto RK; Al-Shawi MK
    Arch Biochem Biophys; 2000 Apr; 376(1):34-46. PubMed ID: 10729188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human P-glycoprotein is active when the two halves are clamped together in the closed conformation.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Biophys Res Commun; 2010 May; 395(3):436-40. PubMed ID: 20394729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
    Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
    Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.